Indian drug cos to benefit as US expedites generic clearances

Indian drug makers, slammed for months in the US over issues related to quality and intellectual property rights, might soon get to breathe easy. The US regulator is set to expedite from October......

Why US doctors want Indian drugs to be banned

In this final part of the three-part series on America's war on substandard Indian generic drugs, Aziz Haniffa speaks about US doctors' contempt for drugs exported from India and the ineptitude of......

India's reaction myopic, irrational, says Ranbaxy whistle-blower

In the second of a three-part series, Ranbaxy whistleblower Dinesh Thakur tells Aziz Haniffa that a formal Congress hearing on spurious drugs from India is being sought. Part I: War on......

Ranbaxy whistle-blower to talk on quality of Made-in-India drugs

The concerns surrounding drug manufacturing practices in India appear to have reached foreign shores, beyond the international regulators’ domain.  Ranbaxy whistle-blower Dinesh Thakur,......